DBV Technologies Reports Financial Results for the First Six Months of 2013
(firmenpresse) - BAGNEUX, FRANCE -- (Marketwired) -- 07/26/13 -- The Board of Directors of DBV Technologies (EURONEXT PARIS: DBV) (ISIN: FR0010417345), the creator of Viaskin®, a new standard in the treatment of allergy, approved the financial statements for the first half 2013on July 25, 2013. The full interim financial report (regulated information) is available on DBV's website, within the Investor Relations section. The 2013 half-year financial statements were subject to a limited review by statutory auditors.
, Chairman and CEO of DBV Technologies, said: "It has been an extremely intense period for DBV Technologies, with key preclinical and clinical data released during two major allergy congresses (AAAAI & EAACI), as well as the co-publication with Assistance Publique-Hôpitaux de Paris (AP-HP) of Arachild's results, demonstrating and efficacy of Viaskin® Peanut after 18 months of treatment." "We are also pleased with our progress in the business development front," continued Dr. Benhamou. "We now have two landmark research collaborations with Mount Sinai Hospital and Pr Malissen from Centre d'Immunologie de Marseille-Luminy. We also engaged in a strategic partnership with Sanofi for the manufacturing of our active principle ingredients and a partnership with Stallergenes, opening new paths and expanding our proprietary Viaskin® platform in respiratory allergies."
Summary financial information (IFRS - subject to a limited review by statutory auditors)
The Company's amounted to EUR 1,336,019 and EUR 1,316,086 for the first halves 2013 and 2012 respectively. These revenues were primarily generated by Research Tax Credit, and to a lesser extent, by the sales of Diallertest®, as well as by subsidies received within the framework of the various research projects conducted by the Company. Sales of Diallertest® remained stable over the period, amounting to EUR 72,735 in the first half 2013 compared with EUR 71,704 a year earlier. This diagnostic product is not of strategic relevance for the Company, which has as its priority the future marketing of products stemming from the Viaskin® platform.
increased significantly by 34% to reach EUR 6,824,121 compared with EUR 5,094,902 a year earlier. This strong variation primarily reflects the reinforcement of teams dedicated to R&D, in an effort to drive the numerous on-going development programmes, including 5 simultaneous trials over the next 24 months.
('G&A') include mainly administrative personnel costs, building costs related to headquarters, and certain fees (such as audit, legal, and consultants' fees). In the first half 2013, G&A expenses reached EUR 2,716,033 compared with EUR 1,796,010 a year earlier. This significant increase results notably from the reinforcement of the Executive Committee, as well as Business Development fees.
The for the first half 2013 amounted to EUR (7,906,957) compared with a EUR (5,432,929) loss for the first half 2012. The loss per share (based on the weighted average number of shares outstanding over the period) amounted to EUR (0.59) and EUR (0.48) for the first halves 2013 and 2012 respectively.
for the first halves 2013 and 2012 stood respectively at EUR (5,634,937) and EUR (6,277,846), primarily fuelled by increasing R&D efforts.
reached EUR 1.1 million in the first half 2013 versus EUR 37.3 million a year earlier subsequently to the Company's IPO on the NYSE-Euronext regulated market.
DBV Technologies will announce its first nine months topline and cash position on October 15, 2013.
DBV Technologies is opening up a decisive new approach to the treatment of allergy -- a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy -- a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).
For more information on DBV Technologies, please visit our website:
CAUTION: Viaskin® is not approved for sale in the USA.
The forward-looking statements, objectives and targets contained herein are based on the Company's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Furthermore, the Research and Development process involves several stages each of which involve the substantial risk that the Company may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Company cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. DBV technologies' business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.
DBV Technologies Reports Financial Results for the First Six Months:
David Schilansky
Chief Financial Officer
Tel. : +33(0)1 55 42 78 75
The Trout Group
Investor Relations
Alan S. Roemer
Tel. : +1 (646) 378-2945
NewCap.
Financial Communication and investor relations
Emmanuel Huynh / Valentine Brouchot
Tel. : +33(0)1 44 71 94 94
Ronald Trahan
APR
Press relations
Ronald Trahan
Tel. : +1 508 359 4005
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.07.2013 - 00:16 Uhr
Sprache: Deutsch
News-ID 1249058
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BAGNEUX, FRANCE
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 114 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Reports Financial Results for the First Six Months of 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
